|
1
|
Aaronson DS and Horvath CM: A road map for
those who don't know JAK-STAT. Science. 296:1653–1655. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hebenst reit D, Horejs-Hoeck J and Duschl
A: JAK/STAT-dependent gene regulation by cytokines. Drug News
Perspect. 18:243–249. 2005. View Article : Google Scholar
|
|
3
|
Hofmann F: The biology of cyclic
GMP-dependent protein kinases. J Biol Chem. 280:1–4. 2005.
View Article : Google Scholar
|
|
4
|
Cook AL and Haynes JM: Protein kinase G
II-mediated proliferative effects in human cultured prostatic
stromal cells. Cell Signal. 16:253–261. 2004. View Article : Google Scholar
|
|
5
|
Swartling FJ, Ferletta M, Kastemar M,
Weiss WA and Westermark B: Cyclic GMP-dependent protein kinase II
inhibits cell proliferation, Sox9 expression and Akt
phosphorylation in human glioma cell lines. Oncogene. 28:3121–3131.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fallahian F, Karami-Tehrani F, Salami S
and Aghaei M: Cyclic GMP induced apoptosis via protein kinase G in
oestrogen receptor-positive and-negative breast cancer cell lines.
FEBS J. 278:3360–3369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Y, Chen Y, Qu R, Lan T and Sang J: Type
II cGMP-dependent protein kinase inhibits EGF-triggered signal
transduction of the MAPK/ERK-mediated pathway in gastric cancer
cells. Oncol Rep. 27:553–558. 2012.
|
|
8
|
Lan T, Chen Y, Sang J, Wu Y, Wang Y, Jiang
L and Tao Y: Type II cGMP-dependent protein kinase inhibits
EGF-induced MAPK/JNK signal transduction in breast cancer cells.
Oncol Rep. 27:2039–2044. 2012.PubMed/NCBI
|
|
9
|
Xie Z, Peng J, Pennypacker SD and Chen Y:
Critical role for the catalytic activity of phospholipase C-gamma1
in epidermal growth factor-induced cell migration. Biochem Biophys
Res Commun. 399:425–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong P, Xu Z, Jia N, Li D and Feng Y:
Elevated expression of p53 gain-of-function mutation R175H in
endometrial cancer cells can increase the invasive phenotypes by
activation of the EGFR/PI3K/AKT pathway. Mol Cancer. 8:1032009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Quesnelle KM, Boehm AL and Grandis JR:
STAT-mediated EGFR signaling in cancer. J Cell Biochem.
102:311–319. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morandell S, Stasyk T, Skvortsov S, Ascher
S and Huber LA: Quantitative proteomics and phosphoproteomics
reveal novel insights into complexity and dynamics of the EGFR
signaling network. Proteomics. 8:4383–4401. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Makki R, Meister M, Pennetier D, Ubeda JM,
Braun A, Daburon V, Krzemień J, Bourbon HM, Zhou R, Vincent A and
Crozatier M: A short receptor downregulates JAK/STAT signalling to
control the Drosophila cellular immune response. PLoS Biol.
8:e10004412010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barré B, Avril S and Coqueret O: Opposite
regulation of myc and p21waf1 transcription by STAT3 proteins. J
Biol Chem. 278:2990–2996. 2003. View Article : Google Scholar
|
|
15
|
Nichane M, Ren X and Bellefroid EJ:
Self-regulation of Stat3 activity coordinates cell-cycle
progression and neural crest specification. EMBO J. 29:55–67. 2010.
View Article : Google Scholar :
|
|
16
|
Wang YH and Huang ML: Organogenesis and
tumorigenesis: Insight from the JAK/STAT pathway in the Drosophila
eye. Dev Dyn. 239:2522–2533. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: How intimate is the relationship? Ann N Y Acad Sci.
1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiong H, Du W, Wang JL, Wang YC, Tang JT,
Hong J and Fang JY: Constitutive activation of STAT3 is predictive
of poor prognosis in human gastric cancer. J Mol Med (Berl).
90:1037–1046. 2012. View Article : Google Scholar
|
|
19
|
Deng JY, Sun D, Liu XY, Pan Y and Liang H:
STAT-3 correlates with lymph node metastasis and cell survival in
gastric cancer. World J Gastroenterol. 16:5380–5387. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Normanno N, Bianco C, De Luca A, Maiello
MR and Salomon DS: Target-based agents against ErbB receptors and
their ligands: A novel approach to cancer treatment. Endocr Relat
Cancer. 10:1–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu T and Li C: Convergence between
Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer. 9:2362010.
View Article : Google Scholar
|
|
22
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Quatrale AE, Porcelli L, Silvestris N,
Colucci G, Angelo A and Azzariti A: EGFR tyrosine kinases
inhibitors in cancer treatment: In vitro and in vivo evidence.
Front Biosci (Landmark Ed). 16:1962–1972. 2011. View Article : Google Scholar
|
|
24
|
Jiang L, Lan T, Chen Y, Sang J, Li Y, Wu
M, Tao Y, Wang Y, Qian H and Gu L: PKG II inhibits EGF/EGFR-induced
migration of gastric cancer cells. PLoS One. 8:e616742013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu M, Chen Y, Jiang L, Li Y, Lan T, Wang Y
and Qian H: Type II cGMP-dependent protein kinase inhibits
epidermal growth factor-induced phosphatidylinositol-3-kinase/Akt
signal transduction in gastric cancer cells. Oncol Lett.
6:1723–1728. 2013.PubMed/NCBI
|
